temozolomide has been researched along with B16 Melanoma in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma." | 7.88 | Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. ( Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D, 2018) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 7.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "First line treatment of metastatic melanoma includes the methylating agent dacarbazine or its analogue temozolomide (TMZ) with improved pharmacokinetics and tolerability." | 7.77 | The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. ( Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P, 2011) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 7.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 5.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| "To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma." | 3.88 | Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. ( Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D, 2018) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 3.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "First line treatment of metastatic melanoma includes the methylating agent dacarbazine or its analogue temozolomide (TMZ) with improved pharmacokinetics and tolerability." | 3.77 | The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. ( Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P, 2011) |
| "The effects of IL-1 receptor antagonist (IL-1Ra), alone and combined with temozolomide and docetaxel chemotherapy, were examined in vitro and in vivo against microscopic and macroscopic mouse B16 melanoma." | 3.76 | Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. ( Aldrich, W; Triozzi, PL, 2010) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 3.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| " In addition, 22b is orally bioavailable across multiple species, crosses the blood-brain barrier, and appears to distribute into tumor tissue." | 1.36 | Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. ( Bontcheva-Diaz, V; Bouska, JJ; Buchanan, FG; Bukofzer, GT; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Park, CH; Penning, TD; Rodriguez, LE; Shi, Y; Thomas, S; Zhu, GD, 2010) |
| "Temozolomide was formulated as a suspension, which was elaborated and evaluated in terms of particle size, shape and agglomeration." | 1.36 | In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. ( Adanja, I; Amighi, K; Debeir, O; Decaestecker, C; Deleuze, P; Hecq, J; Kiss, R; Mathieu, V; Roland, I; Saussez, S; Wauthoz, N, 2010) |
| " In addition, 3a is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide." | 1.35 | Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. ( Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Penning, TD; Shi, Y; Zhu, GD, 2009) |
| " 10b is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast xenograph model in combination with cisplatin." | 1.35 | Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. ( Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Grandel, R; Johnson, EF; Klinghofer, V; Liu, X; Lubisch, W; Luo, Y; Marsh, KC; Olson, AM; Park, CH; Penning, TD; Rosenberg, SH; Shi, Y; Thomas, S; Wernet, W; Zhu, GD, 2008) |
| " Pharmacokinetics studies revealed that GPI 15427 possesses a substantial oral bioavailability (plasma Cmax after a single dose of 40 mg/kg: 1041+/-516 ng/ml)." | 1.33 | Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. ( Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J, 2005) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 1.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| ") was examined using single and daily x5 dosing regimens in athymic mice bearing subcutaneous A375P xenografts." | 1.30 | Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. ( Newlands, ES; Porteous, JK; Wedge, SR, 1997) |
| " The half-life of CCRG 81045 at 37 degrees C in 0." | 1.27 | Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ( Baig, G; Chubb, D; Gibson, NW; Goddard, C; Hickman, JA; Langdon, SP; Slack, JA; Stevens, MF; Stone, R; Vickers, L, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Penning, TD | 4 |
| Zhu, GD | 3 |
| Gandhi, VB | 3 |
| Gong, J | 3 |
| Liu, X | 5 |
| Shi, Y | 5 |
| Klinghofer, V | 3 |
| Johnson, EF | 4 |
| Donawho, CK | 4 |
| Frost, DJ | 5 |
| Bontcheva-Diaz, V | 3 |
| Bouska, JJ | 4 |
| Osterling, DJ | 3 |
| Olson, AM | 4 |
| Marsh, KC | 3 |
| Luo, Y | 5 |
| Giranda, VL | 5 |
| Tong, Y | 1 |
| Ellis, PA | 2 |
| Leverson, J | 1 |
| Marcotte, PA | 1 |
| Przytulinska, M | 1 |
| Rodriguez, LE | 3 |
| Soni, N | 1 |
| Stavropoulos, J | 1 |
| Thomas, S | 3 |
| Park, CH | 2 |
| Fry, EH | 2 |
| Buchanan, FG | 1 |
| Bukofzer, GT | 1 |
| Pinho, JO | 3 |
| Matias, M | 3 |
| Marques, V | 3 |
| Eleutério, C | 3 |
| Fernandes, C | 3 |
| Gano, L | 3 |
| Amaral, JD | 3 |
| Mendes, E | 3 |
| Perry, MJ | 3 |
| Moreira, JN | 3 |
| Storm, G | 3 |
| Francisco, AP | 3 |
| Rodrigues, CMP | 3 |
| Gaspar, MM | 3 |
| Martínez, J | 1 |
| Tarallo, D | 1 |
| Martínez-Palma, L | 1 |
| Victoria, S | 1 |
| Bresque, M | 1 |
| Rodríguez-Bottero, S | 1 |
| Marmisolle, I | 1 |
| Escande, C | 1 |
| Cassina, P | 1 |
| Casanova, G | 1 |
| Bollati-Fogolín, M | 1 |
| Agorio, C | 1 |
| Moreno, M | 1 |
| Quijano, C | 1 |
| Andrade, LNS | 1 |
| Otake, AH | 1 |
| Cardim, SGB | 1 |
| da Silva, FI | 1 |
| Ikoma Sakamoto, MM | 1 |
| Furuya, TK | 1 |
| Uno, M | 1 |
| Pasini, FS | 1 |
| Chammas, R | 1 |
| Da-Costa-Rocha, I | 1 |
| Prieto, JM | 1 |
| Clemente, N | 1 |
| Ferrara, B | 1 |
| Gigliotti, CL | 1 |
| Boggio, E | 1 |
| Capucchio, MT | 1 |
| Biasibetti, E | 1 |
| Schiffer, D | 1 |
| Mellai, M | 1 |
| Annovazzi, L | 1 |
| Cangemi, L | 1 |
| Muntoni, E | 1 |
| Miglio, G | 1 |
| Dianzani, U | 1 |
| Battaglia, L | 1 |
| Dianzani, C | 1 |
| Rocha, CR | 1 |
| Kajitani, GS | 1 |
| Quinet, A | 1 |
| Fortunato, RS | 1 |
| Menck, CF | 1 |
| Lubisch, W | 1 |
| Grandel, R | 1 |
| Wernet, W | 1 |
| Rosenberg, SH | 1 |
| Palma, J | 1 |
| Kinders, R | 1 |
| Donawho, C | 1 |
| Colon-Lopez, M | 1 |
| Saltarelli, M | 1 |
| LeBlond, D | 1 |
| Lin, CT | 1 |
| Wauthoz, N | 1 |
| Deleuze, P | 1 |
| Hecq, J | 1 |
| Roland, I | 1 |
| Saussez, S | 1 |
| Adanja, I | 1 |
| Debeir, O | 1 |
| Decaestecker, C | 1 |
| Mathieu, V | 1 |
| Kiss, R | 1 |
| Amighi, K | 1 |
| Triozzi, PL | 1 |
| Aldrich, W | 1 |
| Tentori, L | 5 |
| Muzi, A | 3 |
| Dorio, AS | 2 |
| Scarsella, M | 4 |
| Leonetti, C | 4 |
| Shah, GM | 1 |
| Xu, W | 3 |
| Camaioni, E | 1 |
| Gold, B | 2 |
| Pellicciari, R | 1 |
| Dantzer, F | 1 |
| Zhang, J | 4 |
| Graziani, G | 5 |
| Mazzon, E | 1 |
| Sau, A | 1 |
| Cuzzocrea, S | 1 |
| Vernole, P | 1 |
| Federici, G | 1 |
| Caccuri, AM | 1 |
| D'Amati, G | 1 |
| Vergati, M | 3 |
| Portarena, I | 1 |
| Kalish, V | 1 |
| Zupi, G | 1 |
| Calvin, D | 1 |
| Morgan, L | 1 |
| Tang, Z | 1 |
| Woznizk, K | 1 |
| Alemu, C | 1 |
| Hoover, R | 1 |
| Lapidus, R | 1 |
| Forini, O | 1 |
| Lacal, PM | 1 |
| Ruffini, F | 1 |
| Li, W | 1 |
| Ko, SH | 1 |
| Ueno, T | 1 |
| Yoshimoto, Y | 1 |
| Yoo, JS | 1 |
| Abdel-Wahab, OI | 1 |
| Abdel-Wahab, Z | 1 |
| Chu, E | 1 |
| Pruitt, SK | 1 |
| Friedman, HS | 1 |
| Dewhirst, MW | 1 |
| Tyler, DS | 1 |
| Wedge, SR | 1 |
| Porteous, JK | 1 |
| Newlands, ES | 1 |
| Middleton, MR | 1 |
| Kelly, J | 1 |
| Goodger, S | 1 |
| Thatcher, N | 1 |
| Margison, GP | 1 |
| Stevens, MF | 1 |
| Hickman, JA | 1 |
| Langdon, SP | 1 |
| Chubb, D | 1 |
| Vickers, L | 1 |
| Stone, R | 1 |
| Baig, G | 1 |
| Goddard, C | 1 |
| Gibson, NW | 1 |
| Slack, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
22 other studies available for temozolomide and B16 Melanoma
| Article | Year |
|---|---|
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Carboplat | 2009 |
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzimidazo | 2009 |
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biol | 2010 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Liposomes; Melanoma, Experimental; Mice; Temozolomide | 2023 |
Mitofusins modulate the increase in mitochondrial length, bioenergetics and secretory phenotype in therapy-induced senescent melanoma cells.
Topics: Animals; Cellular Senescence; Energy Metabolism; Gene Silencing; GTP Phosphohydrolases; Interleukin- | 2019 |
Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Cell-Derived Micro | 2019 |
In Vitro Effects of Selective COX and LOX Inhibitors and Their Combinations with Antineoplastic Drugs in the Mouse Melanoma Cell Line B16F10.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured | 2021 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; | 2018 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cisplatin | 2008 |
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Clinical Trials as Topic; Dacarbazine; D | 2008 |
In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High P | 2010 |
Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Blotting, Western; Ce | 2010 |
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Dacarbazine; Dru | 2010 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacar | 2011 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inh | 2003 |
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blo | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Chemotherapy, Cancer, Regio | 2006 |
Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 1997 |
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Guanine; Huma | 2000 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta | 1987 |